

REMARKS/ARGUMENTS

Claims 1 to 20 were previously presented for examination and the subject of a restriction requirement to which Applicants respond below. Claims 21 to 54 were previously canceled without prejudice. Claims 1 and 2 are currently amended. Claims 9 to 14 are herein canceled without prejudice. Claims 55 to 86 are newly presented. After entry of these amendments, claims 1 to 8, 15 to 20, and 55 to 86 will be pending.

Response to the Restriction Requirement.

Applicants elect Group IV drawn to subject matter wherein Ar¹ is phenyl or naphthyl and amended the claims to conform with the election.

Support for the Amendments to the Claims

Claims 1 and 2 were amended so as to conform to the restriction requirement and election. Support is found *inter alia* in the previous versions of the claims and also in original claims 3 and 15 respectively.

New compound claims 55 to 62 each set forth a member of a Markush group set forth in their respective intervening claims. Support can accordingly be found *inter alia* in their respective antecedents.

New composition claims 63 to 72 set forth compound subject matter of the pending compound claims. Their compound subject matter finds support as set forth above (and in the original compound claims). Their pharmaceutical composition subject matter finds support *inter alia* in the original composition claims.

New methods claims 73 to 86 set forth compound subject matter of the pending compound claims and their compound subject matter finds support accordingly as set forth above. The method subject matter finds support *inter alia* in the original methods claims.

In view of the above, Applicants believe that the amendments to the claims add no new matter and respectfully request their entry.

Appl. No. 10,810,325
Amdt. dated May 9, 2005
Reply to Office Action of April 8, 2005

PATENT

Other Comments

U.S. Patent Application Publication No. 20030088103 (Attorney Docket No. 018781-002130US) is co-pending with pending claims drawn in part to compound subject matter wherein the "Ar¹" of the formulae recited therein is heterocyclic. The case is with Examiner Covington.


U.S. Patent No. 6,620,827 (Attorney Docket No. 018781-002120US) issued with claims drawn in part to subject matter in which the "Ar¹" of the formulae recited therein is phenyl. This case was also with Examiner Covington.

This art has already been made of record.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for examination. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,


Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 415-576-0300
Attachments
FJM:kar
60483425 v1